US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
GB9417742D0
(en)
*
|
1994-09-03 |
1994-10-19 |
Univ Nottingham |
Macrophage stimulating composition
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
PT858343E
(pt)
|
1995-11-02 |
2004-07-30 |
Schering Corp |
Terapia por infusao continua de uma dose baixa de citoquina
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US6472373B1
(en)
*
|
1997-09-21 |
2002-10-29 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
WO1999048535A1
(en)
*
|
1998-03-26 |
1999-09-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
PT1421956E
(pt)
|
1998-04-28 |
2007-07-13 |
Serono Lab |
Processo para a ligação por passos de polietileno glicol ( peg ) a um polipéptido
|
EP2305287A1
(de)
*
|
1998-05-15 |
2011-04-06 |
Schering Corporation |
Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht Antiviral vorbehandelt sind
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
NZ508249A
(en)
*
|
1998-06-08 |
2003-02-28 |
F |
Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
ATE298251T1
(de)
*
|
1998-08-06 |
2005-07-15 |
Mountain View Pharmaceuticals |
Peg-uricase konjugate und verwendung davon
|
SK287491B6
(sk)
|
1998-10-16 |
2010-11-08 |
Biogen Idec Ma Inc. |
Fúzne proteíny interferónu- beta-1a a ich použitie
|
TR200101086T2
(tr)
*
|
1998-10-16 |
2001-08-21 |
Biogen, Inc. |
Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
|
US6824768B2
(en)
*
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
CO5160259A1
(es)
*
|
1999-03-02 |
2002-05-30 |
Schering Corp |
Interferon alfa pegilado en la terapia contra el hiv
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
ATE419001T1
(de)
|
1999-04-08 |
2009-01-15 |
Schering Corp |
Melanoma therapie
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
AU7684000A
(en)
*
|
1999-10-12 |
2001-04-23 |
Santen Pharmaceutical Co. Ltd. |
Interferon complex and medicinal use thereof
|
TR200101086A3
(de)
*
|
1999-10-15 |
2001-08-21 |
|
|
YU32402A
(sh)
|
1999-11-12 |
2005-03-15 |
Maxygen Holdings Ltd. |
Konjugati gama interferona
|
PL356007A1
(en)
|
1999-11-12 |
2004-05-31 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
KR100773323B1
(ko)
|
2000-01-10 |
2007-11-05 |
맥시겐 홀딩스 리미티드 |
지-씨에스에프 접합체
|
EP1908477A3
(de)
*
|
2000-01-24 |
2008-06-11 |
Schering Corporation |
Kombination aus Temozolomid und pegyliertem Interferon-alpha zur Krebsbehandlung
|
US20020009428A1
(en)
*
|
2000-01-24 |
2002-01-24 |
Zaknoen Sara L. |
Combination therapy for cancer
|
WO2001058935A2
(en)
|
2000-02-11 |
2001-08-16 |
Maxygen Aps |
FACTOR VII OR VIIa-LIKE MOLECULES
|
BR0108997A
(pt)
*
|
2000-03-09 |
2003-06-03 |
Schering Corp |
Terapia imune adjuvante para hiv
|
US20030068792A1
(en)
*
|
2000-12-14 |
2003-04-10 |
Yiyou Chen |
Targeted enzymes
|
US20030049689A1
(en)
*
|
2000-12-14 |
2003-03-13 |
Cynthia Edwards |
Multifunctional polypeptides
|
US20080248544A1
(en)
*
|
2000-12-14 |
2008-10-09 |
Murray Christopher J |
Methods And Compositions For Grafting Functional Loops Into A Protein
|
US20030147874A1
(en)
*
|
2000-12-14 |
2003-08-07 |
Volker Schellenberger |
Targeted enzyme prodrug therapy
|
HUP0303251A2
(hu)
|
2001-02-27 |
2003-12-29 |
Maxygen Aps |
Béta-interferon-szerű molekulák
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
UA78726C2
(en)
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
ES2566797T3
(es)
*
|
2002-01-18 |
2016-04-15 |
Biogen Ma Inc. |
Compuestos de polímero de polialquileno y usos de éstos
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
TW200400818A
(en)
|
2002-05-21 |
2004-01-16 |
Wyeth Corp |
Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
MXPA04012709A
(es)
|
2002-06-28 |
2005-09-30 |
Idenix Cayman Ltd |
Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
|
AU2003239774A1
(en)
*
|
2002-07-03 |
2004-01-23 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
AU2003258518B2
(en)
*
|
2002-07-24 |
2007-01-18 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
ES2381617T5
(es)
*
|
2002-08-14 |
2016-02-24 |
Macrogenics, Inc. |
Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
JP2006508918A
(ja)
*
|
2002-09-05 |
2006-03-16 |
ザ ジェネラル ホスピタル コーポレーション |
修飾されたアシアロインターフェロンおよびその使用
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
EP1570269B1
(de)
|
2002-11-25 |
2011-06-08 |
Sciclone Pharmaceuticals, Inc. |
Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin
|
BR0317752A
(pt)
*
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
|
EA008866B1
(ru)
*
|
2002-12-26 |
2007-08-31 |
Маунтин Вью Фамэсьютикэлс, Инк. |
ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1587540B1
(de)
*
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
Identifikation und herstellung von antikörpern mit varianten fc regionen und anwendungsverfahren dafür
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
EP2345661A1
(de)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modifizierte fluorinierte Nukleosidanaloga
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
AP2287A
(en)
|
2003-10-14 |
2011-10-31 |
Intermune Inc |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
|
EP2641611A3
(de)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Kombinationstherapie
|
WO2005058236A2
(en)
|
2003-12-12 |
2005-06-30 |
Genencor International, Inc. |
Cab molecules
|
SG135176A1
(en)
|
2004-02-02 |
2007-09-28 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
WO2005084303A2
(en)
*
|
2004-03-01 |
2005-09-15 |
Enzon Pharmaceuticals, Inc. |
Interferon-beta polymer conjugates
|
JP4699450B2
(ja)
|
2004-04-15 |
2011-06-08 |
ジェネンコー・インターナショナル・インク |
Cab分子、ceaを対象とするadept構築
|
WO2005115452A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
KR101297146B1
(ko)
*
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
인간화 FcγRIIB 특이적 항체 및 그의 사용 방법
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
US20080233100A1
(en)
*
|
2004-06-30 |
2008-09-25 |
Yiyou Chen |
Targeted enzymes
|
AU2009212311B8
(en)
|
2004-07-21 |
2013-05-30 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
AU2005272862B2
(en)
|
2004-08-12 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Stable pegylated interferon formulation
|
EP1809301B1
(de)
|
2004-09-14 |
2019-11-06 |
Gilead Pharmasset LLC |
2-fluoro-2-alkyl-substituierte d-ribonolacton-zwischenprodukte
|
EP1810035A4
(de)
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
Erzeugung von fc-antikörperregionen für effektorfunktion
|
US20080044400A1
(en)
*
|
2004-12-09 |
2008-02-21 |
Volker Schellenberger |
Targeted enzyme prodrug therapy
|
NZ555425A
(en)
|
2004-12-22 |
2010-04-30 |
Ambrx Inc |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
CA2594561C
(en)
|
2004-12-22 |
2014-12-23 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
EP2284191A3
(de)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Prozess zur Herstellung von hGH
|
AU2005323106B2
(en)
|
2004-12-22 |
2010-07-29 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
PL3321359T3
(pl)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Wariantowe postacie oksydazy moczanowej i ich zastosowanie
|
US8101728B2
(en)
*
|
2005-04-28 |
2012-01-24 |
Danisco Us Inc. |
TAB molecules
|
JP2008541769A
(ja)
|
2005-06-03 |
2008-11-27 |
アンブレツクス・インコーポレイテツド |
改善されたヒトインターフェロン分子及びそれらの使用
|
JP2008546708A
(ja)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Hcvにおけるサングリフェリンの使用
|
EP2360170A3
(de)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selektive Reduktion und Derivatisierung von Proteinen die mindestens ein nicht-natives Cystein enthalten
|
US7662370B2
(en)
*
|
2005-06-20 |
2010-02-16 |
Pepgen Corporation |
Low-toxicity, long-circulating human interferon-alpha PEGylated mutants
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
NZ565059A
(en)
|
2005-07-25 |
2011-08-26 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitus C virus replication
|
JP5105485B2
(ja)
|
2005-08-10 |
2012-12-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を有する抗体の同定および工学的改変およびその使用方法
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
EP2339014B1
(de)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
|
AU2007226752A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
CN101466727B
(zh)
|
2006-04-11 |
2012-10-17 |
诺瓦提斯公司 |
Hcv/hiv抑制剂及其用途
|
EP2018437A2
(de)
|
2006-05-02 |
2009-01-28 |
Allozyne, Inc. |
Mit nicht-natürlichen aminosäuren substituierte polypeptide
|
US20080096819A1
(en)
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
WO2008105886A2
(en)
*
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
AU2007281876B2
(en)
|
2006-06-26 |
2013-09-05 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
EP2032159B1
(de)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
|
MX2009002460A
(es)
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Arnt supresor hibrido para celulas de vertebrados.
|
SG174788A1
(en)
|
2006-09-08 |
2011-10-28 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
US20080107629A1
(en)
*
|
2006-09-29 |
2008-05-08 |
Canji, Inc. |
Methods and compositions for gene therapy
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
EA018440B1
(ru)
|
2006-11-24 |
2013-08-30 |
Кадила Хелзкэр Лимитед |
Композиции конъюгатов пэг-интерферон альфа
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
NZ580686A
(en)
|
2007-05-02 |
2012-11-30 |
Ambrx Inc |
Modified interferon beta polypeptides and their uses
|
US7625555B2
(en)
|
2007-06-18 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human interferon-like proteins
|
CA2707840A1
(en)
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
JPWO2009028573A1
(ja)
|
2007-08-27 |
2010-12-09 |
国立大学法人名古屋大学 |
血液凝固障害におけるリバビリンの利用
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
MX338336B
(es)
|
2007-11-20 |
2016-04-07 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
ES2654937T3
(es)
|
2008-04-02 |
2018-02-15 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
ES2587937T3
(es)
|
2008-04-02 |
2016-10-27 |
Macrogenics, Inc. |
Anticuerpos específicos para HER2/neu y métodos para utilizar los mismos
|
WO2010033279A2
(en)
*
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
CN102143947B
(zh)
|
2008-07-08 |
2015-06-24 |
得克萨斯***大学评议会 |
增殖和信号转导及转录激活蛋白激活的新抑制剂
|
PE20110426A1
(es)
|
2008-07-23 |
2011-07-01 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados
|
BRPI0919031A2
(pt)
|
2008-09-26 |
2014-09-23 |
Ambrx Inc |
Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
|
DK2342223T3
(en)
|
2008-09-26 |
2017-07-24 |
Ambrx Inc |
Modified animal erythropoietin polypeptides and their uses
|
PA8855701A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Análogos de nucleósidos
|
EA019295B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Соединения пуриновых нуклеозидов и способ их получения
|
EA019341B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Фосфорамидаты нуклеозидов
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
HUP1200205A3
(en)
|
2009-06-25 |
2012-09-28 |
Savient Pharmaceuticals |
Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
CN102666874B
(zh)
|
2009-10-07 |
2016-06-01 |
宏观基因有限公司 |
由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
|
US8822496B2
(en)
|
2009-10-30 |
2014-09-02 |
Boehringer Ingelheim International Gmbh |
Dosage regimens for HCV combination therapy
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
PE20121799A1
(es)
|
2009-12-21 |
2013-01-02 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos
|
CA2791658C
(en)
|
2010-03-04 |
2019-10-01 |
Macrogenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
WO2011107591A1
(en)
|
2010-03-05 |
2011-09-09 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
AU2011235044A1
(en)
|
2010-03-31 |
2012-11-22 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
JP2013528374A
(ja)
|
2010-05-10 |
2013-07-11 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
Vla4のポリペプチド阻害剤
|
US20120123338A1
(en)
|
2010-06-16 |
2012-05-17 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
MX2013000242A
(es)
|
2010-06-24 |
2014-04-14 |
Panmed Ltd |
Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
LT2605789T
(lt)
|
2010-08-17 |
2019-09-10 |
Ambrx, Inc. |
Modifikuoti relaksino polipeptidai ir jų panaudojimas
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
AU2011311706B2
(en)
|
2010-10-05 |
2015-11-12 |
Debiopharm S.A. |
New treatments of Hepatitis C virus infection
|
EP2624826B1
(de)
|
2010-10-08 |
2018-07-18 |
Novartis AG |
Zusammensetzungen enthaltend vitamin e und sulfamide mit ns3 hemmender wirkung
|
EP3042910B1
(de)
|
2010-11-30 |
2019-01-09 |
Gilead Pharmasset LLC |
2'-spiro-nukleoside zur therapie von hepatitis c
|
MX2013006052A
(es)
|
2010-11-30 |
2013-06-18 |
Novartis Ag |
Nuevos tratamientos de la infeccion por el virus de hepatitis c.
|
JP2014509628A
(ja)
|
2011-03-31 |
2014-04-21 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症を治療するためのアリスポリビル
|
PT2694087E
(pt)
|
2011-04-01 |
2015-04-09 |
Novartis Ag |
Tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
|
US20150104415A1
(en)
|
2011-04-13 |
2015-04-16 |
Debiopharm International Sa |
Treatments of Hepatitis C virus infection
|
EP2726502A1
(de)
|
2011-07-01 |
2014-05-07 |
Bayer Intellectual Property GmbH |
Relaxin-fusionspolypeptide und ihre verwendung
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
WO2013024156A2
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
|
BR112014007247A2
(pt)
|
2011-09-27 |
2017-03-28 |
Novartis Ag |
alisporivir para o tratamento de infecção por vírus da hepatite c
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3135690A1
(de)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
CN102716469B
(zh)
*
|
2012-07-07 |
2013-09-11 |
北京三元基因工程有限公司 |
干扰素α的干粉吸入剂
|
WO2014033266A1
(en)
|
2012-08-31 |
2014-03-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
JP2016529293A
(ja)
|
2013-08-27 |
2016-09-23 |
ギリアド ファーマセット エルエルシー |
2つの抗ウイルス化合物の組合せ製剤
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
EP3183264B1
(de)
|
2014-08-19 |
2020-07-29 |
Biogen MA Inc. |
Pegylierungsverfahren
|
SI3412302T1
(sl)
|
2014-10-24 |
2021-09-30 |
Bristol-Myers Squibb Company |
Modificirani FGF-21 polipeptidi in njihova uporaba
|
AU2016349685A1
(en)
|
2015-11-03 |
2018-03-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of an HBV capsid assembly inhibitor and an interferon
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
PL3471755T3
(pl)
*
|
2016-06-20 |
2020-10-19 |
Elanco Us Inc. |
Pegylowany interferon świni i sposoby jego stosowania
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
BR112019016139A2
(pt)
|
2017-02-08 |
2020-04-07 |
Bristol-Myers Squibb Company |
polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
|
SI3849614T1
(sl)
|
2018-09-11 |
2024-04-30 |
Ambrx, Inc. |
Polipeptidni konjugati interlevkina-2 in njihove uporabe
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
AU2020223031A1
(en)
|
2019-02-12 |
2021-08-19 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-TLR agonist conjugates
|
MX2022011163A
(es)
|
2020-03-11 |
2022-10-18 |
Ambrx Inc |
Conjugados de polipeptidos de interleucina-2 y sus usos.
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|